Koers IMV Inc. Toronto S.E.
Aandelen
IMV
CA44974L3011
Biotechnologie & Medisch Onderzoek
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 30,6 mln. 41,85 mln. 28,53 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -36 mln. -49,23 mln. -33,56 mln. | Nettowinst (verlies) 2022 | -38 mln. -51,97 mln. -35,43 mln. | EV/omzet 2021 | - |
Nettoliquiditeiten 2021 | 18,96 mln. 25,93 mln. 17,68 mln. | Nettoschuld 2022 | 7,67 mln. 10,49 mln. 7,15 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-2,47
x | K/w-verhouding 2022 |
-0,53
x | Werknemers | 63 |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 99,93% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Andrew Hall
CEO | Chief Executive Officer | - | 10-11-20 |
Brittany Davison
DFI | Director of Finance/CFO | - | - |
Chief Operating Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 58 | 01-07-20 | |
Kyle Kuvalanka
BRD | Director/Board Member | 56 | 01-04-21 |
Markus Warmuth
BRD | Director/Board Member | 53 | 06-11-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+4,09% | 43,84 mld. | |
+46,34% | 41,25 mld. | |
+9,45% | 41,68 mld. | |
-10,92% | 27,04 mld. | |
+9,32% | 25,53 mld. | |
-24,87% | 18,18 mld. | |
+29,70% | 12,29 mld. | |
+1,28% | 12,29 mld. | |
+7,78% | 11,15 mld. |